Aki

Inmar Intelligence Names Aki Technologies as its Newly-formed Media Division

Retrieved on: 
Tuesday, April 18, 2023
Stevie Awards, Advertising, Interim, Partnership, Aki Linnanahde, Marcom, Habit, EVP, Aki, CTV, Retail media, PepsiCo, Platform, OwnerIQ, Social media, Fatigue, Cryptocurrency, Sales

Retail Media powered by Aki Moments - Moments targeting enhances retailers’ transaction data with contextual signals to achieve greater scale and acquire new customers across off-platform channels.

Key Points: 
  • Retail Media powered by Aki Moments - Moments targeting enhances retailers’ transaction data with contextual signals to achieve greater scale and acquire new customers across off-platform channels.
  • The division now offers clients triple the resources compared to legacy Aki, with a combined workforce of nearly 500 people.
  • Since Inmar acquired Aki, both companies have collectively received 16 industry awards from Digiday, Marcom, Stevies, Modern Retail, OMMA and others.
  • Together, Inmar and Aki will look to accelerate their industry impact with additional award-winning, high-performing campaigns that drive results and revenue for brands and retailers.

Aki Technologies Recognized for Family Dollar Collaboration with a 2021 Modern Retail Award

Retrieved on: 
Friday, March 11, 2022
DLTR, NASDAQ, Industry, Family, PepsiCo, SAN, Aki, Marketing, Partnership, Path, Advertising, Publication, Food, Family Dollar, CTV, DOOH, MTV Europe Music Award for Best Collaboration, Tree, Technology, Dollar Tree, Highest and best use, Weather, Goal, Digiday, Video game, Interior design, Grocery store, Merchandising, Adweek

"We are thrilled to share this honor of being named a Modern Retail Award winner with Family Dollar," said Aki Technologies CEO, Scott Swanson.

Key Points: 
  • "We are thrilled to share this honor of being named a Modern Retail Award winner with Family Dollar," said Aki Technologies CEO, Scott Swanson.
  • Aki and Family Dollar have a profound and ongoing partnership that has resulted in more than a dozen personalized advertising campaigns since May 2020.
  • In addition to Aki's Modern Retail Award win, Modern Retail shortlisted Aki as a finalist for its Best Use of Video and Best Personalization Strategy categories.
  • In November 2021, Aki was recognized as a 2021 OmniShopper Award winner by the Path to Purchase Institute for its work with PepsiCo.

Aki Technologies Launches Division to Focus on Travel and Tourism

Retrieved on: 
Wednesday, March 9, 2022
Industry, Aki, Tourism, Marketing, Advertising, Travelocity, Adara, ROI, CPG, Wi-Fi, Leadership, CTV, DOOH, Technology, Solution, COVID-19, GDP, Weather, Goal, Awareness, SAN, Travel, Sojern

The World Travel & Tourism Council recently projected U.S. travel and tourism to reach nearly $2 trillion and exceed pre-pandemic levels by 6.2% in 2022.

Key Points: 
  • The World Travel & Tourism Council recently projected U.S. travel and tourism to reach nearly $2 trillion and exceed pre-pandemic levels by 6.2% in 2022.
  • Aki's scalable precision among brand, agency and retail clients in the travel and tourism sector are achieved through its unique moment-based approach.
  • The launch of our travel and tourism vertical is an exciting next step for us to service this exploding market segment.
  • Following CPG and Retail, Travel is the third verticalized division Aki has launched since 2020.

Aki Technologies Enables Data-Driven Personalized Advertising To Better Target Spirits Buyers with ReserveBar

Retrieved on: 
Wednesday, December 1, 2021
CTV, Technology, Advertising, Partnership, Drink, Weather, SAN, Solution, Goal, Marketing, DOOH, CMO, Aki, Sales, Online shopping

SAN FRANCISCO, Dec. 1, 2021 /PRNewswire-PRWeb/ -- Aki Technologies , the leader in moment marketing and personalized advertising, and ReserveBar , the established leader in luxury and super-premium spirits e-commerce, today announced an official partnership giving brands the ability to deliver dynamically personalized digital advertisements to targeted spirits buyers.

Key Points: 
  • SAN FRANCISCO, Dec. 1, 2021 /PRNewswire-PRWeb/ -- Aki Technologies , the leader in moment marketing and personalized advertising, and ReserveBar , the established leader in luxury and super-premium spirits e-commerce, today announced an official partnership giving brands the ability to deliver dynamically personalized digital advertisements to targeted spirits buyers.
  • As published by Path to Purchase Institute in September 2021, top-shelf brand Westward Whiskey tested how dynamically personalized advertising would resonate with audiences interested in buying premium spirits.
  • This ReserveBar partnership continues to elevate Aki as a leader in retail solutions, and this is the first Aki partnership focused solely on premium spirits.
  • Aki Technologies empowers brands and retailers to reach people by targeting pivotal moments in the consumer journey with personalized advertising.

Indigenous-Owned Brand, Cheekbone Beauty, Launches New Film to 'Right the Story', About Representation in the Media

Retrieved on: 
Monday, November 15, 2021
IDEA, Bell Media, Female, Wiikwemkoong First Nation, Unsilent Night, Sid Lee, Music, Education, CAD, Forest Stewardship Council, Institute, CEO, Zygomatic bone, Aki, FSC, Senior, Minister of Diversity, Inclusion and Youth, Inclusivism, Growth, First Nations, Equity, European Association of Communication Agencies, Sale, Partnership, Sephora, Team, Indigenous peoples, Marketing, BIPOC, Story, Square One, Yukon, Pacific Centre, ICA, Climate, Chinook Centre, Life, Ojibwe, Tears, City, Entertainment, Cosmetics, Public relations

TORONTO, Nov. 15, 2021 /CNW Telbec/ - Cheekbone Beauty launches 'Right the Story,' an act to reclaim the narrative surrounding Indigenous peoples in the media.

Key Points: 
  • TORONTO, Nov. 15, 2021 /CNW Telbec/ - Cheekbone Beauty launches 'Right the Story,' an act to reclaim the narrative surrounding Indigenous peoples in the media.
  • In collaboration with creative agency Sid Lee, this campaign challenges stereotypes and underrepresentation by amplifying the voices of unsung Indigenous heroes.
  • Sid Lee did an incredible job bringing Cheekbone Beauty's vision to life and Sephora has been tremendously supportive every step of the way.
  • Cheekbone Beauty strongly believes in representing diversity and inclusion within Indigenous communities, which is also reflected in all aspects of the film and out-of-home pieces.

Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

Retrieved on: 
Thursday, August 5, 2021
Company, Plastic, Lung, Phase, COVID-19, Canadian Securities Administrators, Infection, Inflammation, Science, Lead, Blockchain.com, Data analysis, Arch, Aki, Patient, Database, Severe acute respiratory syndrome coronavirus 2, OTC Markets Group, News, Cell, Endothelium, Acute kidney injury, Liver, Safety, Death, End organ damage, GLOBE, Pharmaceutical industry, Antibiotics

All of the Phase II clinical sites in Canada, the U.S. and Turkey have been officially closed.

Key Points: 
  • All of the Phase II clinical sites in Canada, the U.S. and Turkey have been officially closed.
  • LSALT peptide(also known as Metablok) is a noveltherapeutic agent and the lead DPEP-1 inhibitor in the Arch peptide drug pipeline.
  • Additional information about the Phase II trial can be found at:
    The Phase II results will be used to design the Phase III program, including greater patient numbers to more fully evaluate efficacy and safety in COVID-19 patients.
  • For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com .

Acute Kidney Injury (AKI) Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Health, General Health, Kidney diseases, Medical emergencies, Acute kidney injury, Organ failure, Aki, Branches of biology, Renal angina

The "Acute Kidney Injury (AKI) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Kidney Injury (AKI) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Acute Kidney Injury - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), And Japan.
  • The mortality adjusted incident population of AKI in hospitalized patients in the seven major market, was estimated to be 6,544,569 in 2020.
  • In the United States, mortality adjusted incident population of AKI in hospitalized patients accounted for 2,231,147 in 2020.

Global Acute Kidney Injury (AKI) Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Health, General Health, Kidney diseases, Organ failure, Acute kidney injury, Aki, Branches of biology, Renal angina

The "Acute Kidney Injury (AKI) - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Kidney Injury (AKI) - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Acute Kidney Injury (AKI) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the AKI, historical and forecasted epidemiology as well as the AKI market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acute Kidney Injury?
  • Out of the above-mentioned countries, which country would have the highest incident population of Acute Kidney Injury during the forecast period (2021-2030)?

Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, FDA, Managed care, Other Health, Health, Radiology, Pharmaceutical, Other Science, Research, Science, Clinical trials, Branches of biology, Animal physiology, Cell biology, Human physiology, Metabolic pathways, Cytochrome P450, Epoxyeicosatrienoic acid, Acute kidney injury, Aki, Kidney, NPH-022, Nephraegis Therapeutics, Inc., Xontogeny, LLC, NPH-022, NEPHRAEGIS THERAPEUTICS, INC., XONTOGENY, LLC

b"Nephraegis Therapeutics, Inc., a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI) today announced their launch with a seed investment from Xontogeny, LLC to advance their lead compound through critical preclinical work.\nThis press release features multimedia.

Key Points: 
  • b"Nephraegis Therapeutics, Inc., a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI) today announced their launch with a seed investment from Xontogeny, LLC to advance their lead compound through critical preclinical work.\nThis press release features multimedia.
  • Nephraegis' lead compound, NPH\xe2\x80\x91022, acts via the same pathway as endogenous epoxyeicosatrienoic acids (EETs), which regulate normal kidney function to respond to cellular stress events such as hypoxia or chemotoxicity.
  • This is especially important for our initial target, developing NPH-022 as a potentially promising new treatment to prevent AKI.\xe2\x80\x9d\nAKI is an abrupt loss of kidney function.
  • Nephraegis Therapeutics undertakes no obligation to update any forward-looking statements for any reason.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005296/en/\n"

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Retrieved on: 
Thursday, April 29, 2021
Medical specialties, Anatomy, Branches of biology, Kidney diseases, Organ failure, Vifor Pharma, Acute kidney injury, Aki, Acute respiratory distress syndrome

b'UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion\xe2\x80\x99s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI).

Key Points: 
  • b'UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion\xe2\x80\x99s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI).
  • Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma Group commented: \xe2\x80\x9cWe are excited that enrollment in the AKI-002-15 Phase 2 trial has completed.
  • The first dose was given within four hours of the completion of surgery with subsequent doses given at 24-hour intervals.
  • Enrollment is complete in a Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a Phase 2 exploratory trial in cardiac-surgery associated acute kidney injury, and a Phase 2 exploratory trial in patients with acute lung injury associated with COVID-19 pneumonia.